The epidemiology of depression and the evolution of treatment

Robert M A Hirschfeld

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Depression is a prevalent and pernicious disorder. About 1 in 5 US adults have at least 1 lifetime episode of major depression. Of those with depression, the majority will relapse over the long-term and many will have poor mental health outcomes and psychosocial disabilities. Over the past century, a range of treatments, including medications with varying mechanisms of action, have been developed to manage depression. Treatments from seizure therapies to an array of medications-amphetamine, tricyclic antidepressants, monoamine oxidase inhibitors, mixed-action antidepressants, selective serotonin reuptake inhibitors, and dual reuptake inhibitors - have evolved.

Original languageEnglish
Pages (from-to)5-9
Number of pages5
JournalJournal of Clinical Psychiatry
Volume73
Issue numberSUPPL. 1
DOIs
StatePublished - 2012

Fingerprint

Epidemiology
Depression
Monoamine Oxidase Inhibitors
Tricyclic Antidepressive Agents
Serotonin Uptake Inhibitors
Amphetamine
Antidepressive Agents
Mental Health
Seizures
Recurrence
Antidepressants
Medication
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Arts and Humanities (miscellaneous)

Cite this

The epidemiology of depression and the evolution of treatment. / Hirschfeld, Robert M A.

In: Journal of Clinical Psychiatry, Vol. 73, No. SUPPL. 1, 2012, p. 5-9.

Research output: Contribution to journalArticle

Hirschfeld, Robert M A. / The epidemiology of depression and the evolution of treatment. In: Journal of Clinical Psychiatry. 2012 ; Vol. 73, No. SUPPL. 1. pp. 5-9.
@article{b364e793a4e74e17a5a977bcef6dded0,
title = "The epidemiology of depression and the evolution of treatment",
abstract = "Depression is a prevalent and pernicious disorder. About 1 in 5 US adults have at least 1 lifetime episode of major depression. Of those with depression, the majority will relapse over the long-term and many will have poor mental health outcomes and psychosocial disabilities. Over the past century, a range of treatments, including medications with varying mechanisms of action, have been developed to manage depression. Treatments from seizure therapies to an array of medications-amphetamine, tricyclic antidepressants, monoamine oxidase inhibitors, mixed-action antidepressants, selective serotonin reuptake inhibitors, and dual reuptake inhibitors - have evolved.",
author = "Hirschfeld, {Robert M A}",
year = "2012",
doi = "10.4088/JCP.11096su1c.01",
language = "English",
volume = "73",
pages = "5--9",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - The epidemiology of depression and the evolution of treatment

AU - Hirschfeld, Robert M A

PY - 2012

Y1 - 2012

N2 - Depression is a prevalent and pernicious disorder. About 1 in 5 US adults have at least 1 lifetime episode of major depression. Of those with depression, the majority will relapse over the long-term and many will have poor mental health outcomes and psychosocial disabilities. Over the past century, a range of treatments, including medications with varying mechanisms of action, have been developed to manage depression. Treatments from seizure therapies to an array of medications-amphetamine, tricyclic antidepressants, monoamine oxidase inhibitors, mixed-action antidepressants, selective serotonin reuptake inhibitors, and dual reuptake inhibitors - have evolved.

AB - Depression is a prevalent and pernicious disorder. About 1 in 5 US adults have at least 1 lifetime episode of major depression. Of those with depression, the majority will relapse over the long-term and many will have poor mental health outcomes and psychosocial disabilities. Over the past century, a range of treatments, including medications with varying mechanisms of action, have been developed to manage depression. Treatments from seizure therapies to an array of medications-amphetamine, tricyclic antidepressants, monoamine oxidase inhibitors, mixed-action antidepressants, selective serotonin reuptake inhibitors, and dual reuptake inhibitors - have evolved.

UR - http://www.scopus.com/inward/record.url?scp=84864852608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864852608&partnerID=8YFLogxK

U2 - 10.4088/JCP.11096su1c.01

DO - 10.4088/JCP.11096su1c.01

M3 - Article

VL - 73

SP - 5

EP - 9

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 1

ER -